Related Experiment Video
Updated: Feb 28, 2026
06:45
Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
3.6K
[Pramipexole in Parkinson's disease].
N N Shindriaeva1, O A Gankina1, O S Levin1
1Russian Medical Academy of Postgraduate Education, Moscow, Center for Movement Disorders, Moscow.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|June 22, 2017
Summary
Pramipexole, a dopamine receptor agonist, effectively treats Parkinson's disease (PD). This review covers optimal dosing, use in early and advanced PD, and its effects on motor and non-motor symptoms.
Area of Science:
- Pharmacology
- Neuroscience
- Movement Disorders
Context:
- Parkinson's disease (PD) is a progressive neurodegenerative disorder.
- Dopamine receptor agonists are a key therapeutic class for PD management.
- Pramipexole is a widely used non-ergoline dopamine agonist.
Purpose:
- To review the efficacy and safety of pramipexole in Parkinson's disease.
- To summarize optimal treatment strategies for pramipexole initiation and titration.
- To evaluate pramipexole's effects on various PD symptoms, including motor and non-motor features.
Summary:
- Pramipexole demonstrates efficacy across early and advanced stages of Parkinson's disease.
- Optimal starting doses and titration schedules are crucial for maximizing therapeutic benefit and minimizing side effects.
- The drug shows benefits for tremor, cognitive impairment, and affective disturbances in PD patients.
- Safety profile is generally favorable, with common side effects including nausea and somnolence.
Impact:
- Provides clinicians with evidence-based guidance on pramipexole use in Parkinson's disease.
- Highlights the role of pramipexole in managing both motor and non-motor symptoms.
- Contributes to optimizing patient outcomes and quality of life in Parkinson's disease management.
More Related Videos
Related Concept Videos
01:24Parkinson's Disease: Treatment
1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
01:15Parkinson's Disease: Overview
2.2K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.2K
01:22Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.9K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.9K
01:37Neural Regulation
43.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.8K
01:26Cholinergic Antagonists: Therapeutic Uses
1.6K
Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
1.6K